

REMARKS


Claims 1-14, 16-23 and 27-32 are all the claims under consideration in the application.

Claims 15, 24, 25 and 26 are cancelled. New Claims 29-32 are added.

A cross-reference to the parent application is added after the title. No new matter is added. New Claims 29-32 recite the subject matter of cancelled Claims 15, 24, 25 and 26, respectively.

Applicants request prosecution of this application on the merits.

Respectfully submitted,



David R. Kurlandsky
Reg. No. 41,505
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-7304
Fax (734) 622-1553

Attachment - Amended claims, Version with markings to show changes made

DK1P4439.doc

VERSION WITH MARKINGS TO SHOW CHANGES MADEIN THE CLAIMS:

Cancel Claims 15, 24, 25 and 26.

Add the following new Claims 29-32.

Claim 29 (new). A compound according to Claim 5 which is selected from N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-chloronaphthalene; N-Propionyl, N-(2-Diethylaminoethyl)-4-amino-9-fluorenone; N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-bromonaphthalene; N-Propionyl, N-(N-Morpholino)-1-amino-4-chloronaphthalene; N-Propionyl, N-(2-(3-diethylamino-propyl))-1-amino-4-chloronaphthalene; N-Propionyl, N-(2-Diethylaminoethyl)-1-4-azidonaphthalene; N-Propionyl, N-(2-Diethylaminoethyl)-3-chlorobenzyl-amine; N-Propionyl, N-(2-Diethylaminoethyl)-3-bromobenzyl-amine; N-Propionyl, N-(2-Piperidylethyl)-1-amino-4-chloronaphthalene; N-Propionyl, N-(2-(3-dimethylamino-propyl))-1-amino-4-chloronaphthalene; N-Propionyl, N-(2-Dimethylaminoethyl)-1-amino-4-chloronaphthalene; N-Propionyl, N-(2-(N-benzyl)-aminoethyl)-1-aminonaphthalene; N-(2-Diethylamino-ethyl)-N-(7-methyl-quinolin-4-yl)-propionamide; N-Acryloyl, N-(2-diethylaminoethyl)-1-amino-4-chloronaphthalene; and N-Propionyl, N-(2-Diethylaminoethyl)-(1-amino-4-nitronaphthalene).

Claim 30 (new). A compound according to Claim 1 which is a pharmaceutically acceptable salt.

Claim 31 (new). A pharmaceutical formulation comprising a compound of Claim 1 together with a pharmaceutically acceptable diluent, carrier or excipient therefor.

Claim 32 (new). A method for treating a CNS disorder in a mammal in need of treatment comprising administering a CNS effective amount of a compound of Claim 1.